Last reviewed · How we verify

Placebo Gefitinib — Competitive Intelligence Brief

Placebo Gefitinib (Placebo Gefitinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

phase 3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo Gefitinib (Placebo Gefitinib) — Nanjing Sanhome Pharmaceutical, Co., Ltd.. This is a placebo control arm, not an active drug, and contains no therapeutic mechanism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo Gefitinib TARGET Placebo Gefitinib Nanjing Sanhome Pharmaceutical, Co., Ltd. phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo Gefitinib — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-gefitinib. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: